IMDX

+ Watchlist + Portfolio

Insight Molecular Diagnostics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.38
52-Week Range: $2.33 – $8.51
Market Cap: $140.71M
P/E (TTM): —
EPS (TTM): -1.52
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -57.82%
Gross Margin: 48.74%
Operating Margin: -3815.06%
Profit Margin: 0.00%
Current Ratio: 2.00
Debt/Equity: —
Total Debt: $2.63M
Free Cash Flow: $-18.79M
Revenue Growth: -53.90%
Earnings Growth: —
Enterprise Value: $128.20M

IMDX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$958.00K	$1.50M	$1.88M	$4.05M
Cost of Revenue	$976.00K	$1.09M	$1.14M	$1.76M
Gross Profit	-$18.00K	$413.00K	$740.00K	$2.30M
Research & Development	$7.30M	$9.29M	$9.84M	$15.90M
Selling, General & Admin	$21.53M	$13.29M	$13.79M	$16.11M
Operating Expenses	$28.83M	$22.83M	$23.99M	$32.88M
Operating Income	-$28.85M	-$22.42M	-$23.25M	-$30.58M
EBITDA	-$13.31M	-$23.12M	-$59.02M	-$47.92M
Pretax Income	-$18.61M	-$24.86M	-$60.66M	-$50.22M
Income Tax	$0.00	—	—	—
Net Income	-$72.90M	-$27.78M	-$60.66M	-$50.22M
Diluted EPS	-20.00	-3.75	-4.66	-1.65
Diluted Shares	5.54M	7.65M	13.07M	30.48M

IMDX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.99M	$9.43M	$8.64M	$11.58M
Receivables	$2.01M	$484.00K	$1.61M	$1.13M
Inventory	—	$0.00	$410.00K	$446.00K
Current Assets	$25.54M	$10.70M	$11.76M	$15.31M
Total Assets	$100.09M	$74.89M	$35.08M	$25.76M
Current Liabilities	$12.11M	$7.19M	$7.28M	$12.07M
Total Debt	$3.54M	$2.87M	$3.66M	$3.50M
Total Liabilities	$65.80M	$54.42M	$47.35M	$57.22M
Retained Earnings	-$260.68M	-$289.88M	-$350.54M	-$400.76M
Shareholders' Equity	$34.29M	$20.47M	-$12.27M	-$31.46M
Working Capital	$13.43M	$3.50M	$4.48M	$3.23M

IMDX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$45.57M	-$23.32M	-$20.69M	-$22.18M
Capital Expenditure	-$4.34M	-$281.00K	-$516.00K	-$3.19M
Free Cash Flow	-$49.91M	-$23.61M	-$21.20M	-$25.37M
Depreciation & Amortisation	$5.22M	$1.68M	$1.56M	$2.20M
Stock-Based Compensation	$10.04M	$2.89M	$1.91M	$2.38M
Investing Cash Flow	-$4.34M	-$932.00K	-$512.00K	-$3.19M
Financing Cash Flow	$35.81M	$12.19M	$20.43M	$28.07M
Share Repurchases	$0.00	-$1.12M	-$5.39M	$0.00
Net Change in Cash	-$14.10M	-$12.07M	-$772.00K	$2.70M

IMDX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.14M	$518.00K	$260.00K	$1.14M	$32.00K
Cost of Revenue	$813.00K	$168.00K	$121.00K	$643.00K	$17.00K
Gross Profit	$1.32M	$350.00K	$139.00K	$496.00K	$15.00K
Research & Development	$2.92M	$3.28M	$3.88M	$5.83M	$4.95M
Selling, General & Admin	$4.14M	$3.83M	$3.70M	$4.38M	$5.14M
Operating Expenses	$7.25M	$7.32M	$7.81M	$10.45M	$10.35M
Operating Income	-$5.92M	-$6.97M	-$7.67M	-$9.95M	-$10.33M
EBITDA	-$6.15M	-$9.16M	-$10.24M	-$22.37M	-$3.64M
Pretax Income	-$6.67M	-$9.74M	-$10.85M	-$22.95M	-$4.29M
Income Tax	$0.00	$0.00	$0.00	—	$0.00
Net Income	-$6.67M	-$9.74M	-$10.85M	-$22.95M	-$4.29M
Diluted EPS	-0.26	-0.30	-0.34	-0.72	-0.12
Diluted Shares	25.69M	32.02M	32.03M	32.06M	34.52M

IMDX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$31.03M	$24.29M	$18.69M	$11.58M	$28.20M
Receivables	$3.54M	$512.00K	$258.00K	$1.13M	$157.00K
Inventory	$459.00K	$693.00K	$471.00K	$446.00K	$382.00K
Current Assets	$36.26M	$26.84M	$21.39M	$15.31M	$30.52M
Total Assets	$60.36M	$50.52M	$43.94M	$25.76M	$40.43M
Current Liabilities	$9.68M	$6.65M	$7.66M	$12.07M	$12.01M
Total Debt	$3.48M	$3.37M	$3.13M	$3.50M	$3.07M
Total Liabilities	$50.14M	$49.42M	$53.13M	$57.22M	$51.12M
Retained Earnings	-$357.21M	-$366.95M	-$377.81M	-$400.76M	-$405.05M
Shareholders' Equity	$10.22M	$1.10M	-$9.20M	-$31.46M	-$10.69M
Working Capital	$26.58M	$20.19M	$13.73M	$3.23M	$18.51M

IMDX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.84M	-$6.30M	-$4.50M	-$5.54M	-$7.64M
Capital Expenditure	-$307.00K	-$349.00K	-$1.05M	-$1.48M	-$613.00K
Free Cash Flow	-$6.15M	-$6.65M	-$5.55M	-$7.02M	-$8.25M
Depreciation & Amortisation	$491.00K	$559.00K	$584.00K	$563.00K	$631.00K
Stock-Based Compensation	$487.00K	$578.00K	$559.00K	$759.00K	$647.00K
Investing Cash Flow	-$307.00K	-$349.00K	-$1.05M	-$1.48M	-$613.00K
Financing Cash Flow	$28.56M	-$114.00K	-$120.00K	-$252.00K	$24.70M
Share Repurchases	—	—	$0.00	$0.00	—
Net Change in Cash	$22.41M	-$6.76M	-$5.67M	-$7.28M	$16.45M

Market Snapshot

About

Insight Molecular Diagnostics Inc. is a molecular diagnostics company focused on developing and commercializing proprietary diagnostic tests for cancer detection and monitoring. The company's products utilize advanced molecular biology techniques to analyze genetic markers and provide clinically actionable information. Insight Molecular Diagnostics targets oncology applications where precision diagnostics can guide treatment decisions. The company serves hospitals, reference laboratories, and oncology practices.